ArticleOman journal of ophthalmology
Short-term efficacy and safety of intravitreal brolucizumab in diabetic macular edema: A retrospective interventional study.
Article in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to evaluate the efficacy and safety of intravitreal brolucizumab (IVBr), a novel antivascular endothelial growth factor agent, in the treatment of diabetic macular edema (DME) by assessing both functional (visual) and structural (anatomical) improvements. MATERIALS AND
methodsA retrospective, interventional study was conducted at the ophthalmology outpatient department of Sultan Qaboos University Hospital at University Medical City. A cohort of twenty patients (60 injections) with DME received three IVBr injections (6 mg/0.05 mL) over 18 weeks. This cohort consists of 10 male and 10 female patients, with a mean age of 57.1 years (range: 35-81; standard deviation [SD] 14.37). The best-corrected visual acuity (BCVA) was measured and recorded in equivalent logMAR. The subfoveal macular thickness (SFMT) was assessed with optical coherence tomography. Statistical analysis was carried out using paired
resultsThe BCVA improved significantly from a baseline mean of logMar 0.36 (SD 0.7) to 0.22 (SD 0.5) after the third injection (
conclusionThe study findings in this cohort demonstrated statistically significant improvement in BCVA and a substantial decrease in SFMT. However, more real-world studies are required to enhance the validation of this study's findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.